权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Intestinal T cells and microbiota as therapeutic targets in autoimmune uveitis

肠道 T 细胞和微生物群作为自身免疫性葡萄膜炎的治疗靶点

基本信息

批准号：
10275312
负责人：
Phoebe Lin
金额：
$ 48.97万
依托单位：
OREGON HEALTH & SCIENCE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-01 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10275312
关键词：
Address Adoptive Transfer Affect Animals Anti-Inflammatory Agents Antibiotics Arthritis Autoimmune Diseases Bacteria Biological Assay Biological Markers Blindness Body part Cells Chronic Dietary Fiber Disease Disease Pathway Equilibrium Eye Fermentation Frequencies Goals Homeostasis Immune Immune system Immunity Immunophenotyping In Vitro Inflammation Inflammatory Intervention Intestinal permeability Intestines Left Link Lymphoid Tissue Measures Mediating Medical Metronidazole Modeling Morphology Mus Pathogenesis Peripheral Production Propionates Proteins Regulatory T-Lymphocyte Severities T-Lymphocyte Testing Time Transgenic Organisms Uveitis Volatile Fatty Acids autoimmune uveitis cell motility cell type drinking water effector T cell fecal transplantation gut microbiota improved in vivo inflammatory disease of the intestine insight intestinal barrier intestinal epithelium intestinal homeostasis microbial microbiota microorganism migration mouse model new therapeutic target novel novel strategies prevent protective effect side effect therapeutic target trafficking treatment strategy

项目摘要

Project Summary Chronic autoimmune uveitis represents a medical management conundrum, which left untreated, is a significant cause of blindness in the US and worldwide. Yet due to an incomplete understanding of its pathogenesis, treatment has often required use of non-specific anti-inflammatory agents that can have untoward side effects. Emerging evidence links the intestinal microbiota to extraintestinal autoimmune diseases like uveitis, providing new clues into pathogenesis, and novel avenues for therapeutic targeting. Our goal is to investigate how the intestinal microbiota can be manipulated to re-establish intestinal and thus systemic immune homeostasis that has gone awry during the course of autoimmune uveitis. To do this, we are using a quintessential T-cell mediated model, experimental autoimmune uveitis (EAU). We will utilize two different interventions to alter the intestinal microbiota, antibiotics and short chain fatty acid (SCFA) metabolites of intestinal bacterial fermentation of dietary fiber, in EAU. Enhancement of intestinal Tregs (cells that usually suppress the immune system) by these microbiota-altering interventions will be tested by adoptive transfer of Tregs and in vitro Treg suppression assays. The impact of microbiota-altering interventions on intestinal immune cell migration to peripheral lymphoid tissues and the eye during EAU will also be investigated. Direct microbiota effects on enhancement of intestinal Treg abundance and uveitis severity will be tested by fecal microbial transplantation from antibiotic or SCFA-pre-treated animals. These results are expected to yield novel insights into autoimmune uveitis pathogenesis as well as lay groundwork for new treatment strategies targeting the intestinal microbiota to re-establish immune homeostasis.

项目摘要慢性自身免疫性葡萄膜炎是一个医学管理难题，如果不治疗，在美国和全世界都是致盲的重要原因。然而，由于对它的不完全理解，在发病机制中，治疗通常需要使用非特异性抗炎剂，不良副作用新出现的证据将肠道微生物群与肠外自身免疫联系起来这为研究葡萄膜炎等疾病的发病机制提供了新的线索，并为治疗靶向提供了新的途径。我们目的是研究如何操纵肠道微生物群来重建肠道，在自身免疫性葡萄膜炎的过程中，系统免疫稳态发生了变化。要做到这一点，我们使用典型的T细胞介导的模型，实验性自身免疫性葡萄膜炎（EAU）。我们将利用两个改变肠道菌群、抗生素和短链脂肪酸（SCFA）代谢物的不同干预措施肠道细菌发酵的膳食纤维，在EAU。增强肠道THP（细胞通常抑制免疫系统），将通过过继转移来测试这些改变微生物群的干预措施。 Treg和体外Treg抑制测定。微生物改变干预对肠道菌群的影响还将研究EAU期间免疫细胞向外周淋巴组织和眼睛的迁移。直接微生物群对肠Treg丰度和葡萄膜炎严重程度的增强的作用将通过粪便试验来测试。来自抗生素或SCFA预处理的动物的微生物移植。预计这些结果将产生对自身免疫性葡萄膜炎发病机制的新见解以及为新的治疗策略奠定基础靶向肠道微生物群以重建免疫稳态。